Novo Nordisk A/S (NVO, Pharmaceuticals) Stock Valuation & Fair Value Fairly valued
Novo Nordisk A/S (NVO, Pharmaceuticals) trades at a blended P/E of 12.5 — about 48% below its historical normal valuation — with a forward growth estimate of 1.8% and a PEG of 6.77. Analysts' one-year estimates have been hit 73% of the time.
Valuation flags
- High PEG (6.8x)
- Low growth forecast
Verdict history
tickerseer's rating has been fairly valued since 2026-06-14.
Frequently asked questions
Is Novo Nordisk A/S stock overvalued?
At a blended P/E of 12.5 versus its historical normal P/E of 24.0, Novo Nordisk A/S trades about 48% below its typical valuation, with a PEG of 6.77 on 1.8% forward growth — tickerseer currently rates it fairly valued.
What is Novo Nordisk A/S's fair value and PEG?
Novo Nordisk A/S trades at a blended P/E of 12.5 against a historical normal P/E of 24.0, a PEG of 6.77, and a forward growth estimate of 1.8%.
Has tickerseer's rating of Novo Nordisk A/S changed?
tickerseer's rating has been fairly valued since 2026-06-14.
Industry: Pharmaceuticals. Create a free account to unlock the full analysis — the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.